Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Anxiety Disorders 2Weight Loss 1Recurrence 1Lung Neoplasms 1Glioma 1Fatigue 1Depression 1Colorectal Adenocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Cachexia 1Brain Neoplasms 1Advanced Cancer 1Adenocarcinoma of Lung 1

Interventions

Megestrol Acetate 9Exercise 6Standard of Care 4Olanzapine 3Ibuprofen 3Blood Specimen Collection 3anamorelin 2Resistance Training 2Physical Therapy Modalities 2Nutrition Assessment 2Mirtazapine 2Melatonin 2Infliximab 2Dietary Supplements 2Diet Therapy 2Cyproheptadine 2testosterone enanthate 1remune 1ostarine 1olanzapine-fluoxetine combination 1nabiximols 1nabilone 1irinotecan sucrosofate 1fucoidan 1dermcidin 1clazakizumab 1bermekimab 1alkaloid GB18 1Vitamin D 1Sodium Chloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Cachexia × Fluoxetine × Clear all
NCT00489593 2015-01-08

Olanzapine in Patients With Advanced Cancer and Weight Loss

M.D. Anderson Cancer Center

Phase 1 Completed
57 enrolled

Cachexia, Weight Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡